294 related articles for article (PubMed ID: 23461787)
1. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit.
Brogan SE; Winter NB; Abiodun A; Safarpour R
Pain Med; 2013 Apr; 14(4):478-86. PubMed ID: 23461787
[TBL] [Abstract][Full Text] [Related]
2. Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary.
Brogan SE; Winter NB
Pain Med; 2011 Dec; 12(12):1758-68. PubMed ID: 22054042
[TBL] [Abstract][Full Text] [Related]
3. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction.
Brogan SE; Winter NB; Okifuji A
Reg Anesth Pain Med; 2015; 40(4):369-75. PubMed ID: 25923819
[TBL] [Abstract][Full Text] [Related]
4. Medical cost impact of intrathecal drug delivery for noncancer pain.
Guillemette S; Witzke S; Leier J; Hinnenthal J; Prager JP
Pain Med; 2013 Apr; 14(4):504-15. PubMed ID: 23480485
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up.
Atli A; Theodore BR; Turk DC; Loeser JD
Pain Med; 2010 Jul; 11(7):1010-6. PubMed ID: 20492572
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal narcotic infusion pumps for intractable pain of chronic pancreatitis: a pilot series.
Kongkam P; Wagner DL; Sherman S; Fogel EL; Whittaker SC; Watkins JL; McHenry L; Lehman GA
Am J Gastroenterol; 2009 May; 104(5):1249-55. PubMed ID: 19367269
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal Morphine Infusion Therapy in Management of Chronic Pain: Present and Future Implementation in Korea.
Kim EJ; Moon JY; Kim YC; Park KS; Yoo YJ
Yonsei Med J; 2016 Mar; 57(2):475-81. PubMed ID: 26847303
[TBL] [Abstract][Full Text] [Related]
9. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
Enting RH; Oldenmenger WH; van der Rijt CC; Wilms EB; Elfrink EJ; Elswijk I; Sillevis Smitt PA
Cancer; 2002 Jun; 94(11):3049-56. PubMed ID: 12115396
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis of patient-controlled analgesia compared to continuous elastomeric pump infusion of tramadol and metamizole].
Hernández García D; Lara Vila I; Caba Barrientos F; Ramos Curado P; Núñez García A; Echevarría Moreno M
Rev Esp Anestesiol Reanim; 2007 Apr; 54(4):213-20. PubMed ID: 17518171
[TBL] [Abstract][Full Text] [Related]
11. Outcome of intrathecal opioids in chronic non-cancer pain.
Roberts LJ; Finch PM; Goucke CR; Price LM
Eur J Pain; 2001; 5(4):353-61. PubMed ID: 11743701
[TBL] [Abstract][Full Text] [Related]
12. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intrathecal drug delivery system for refractory cancer pain patients: a single tertiary medical center experience.
Lin CP; Lin WY; Lin FS; Lee YS; Jeng CS; Sun WZ
J Formos Med Assoc; 2012 May; 111(5):253-7. PubMed ID: 22656395
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.
Ripamonti C; Brunelli C
J Clin Oncol; 2003 Jul; 21(14):2801-2; author reply 2802-3. PubMed ID: 12860959
[No Abstract] [Full Text] [Related]
15. Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management: a retrospective analysis of 365 patients.
Bolash R; Udeh B; Saweris Y; Guirguis M; Dalton JE; Makarova N; Mekhail N
Neuromodulation; 2015 Feb; 18(2):150-5; discussion 155-6. PubMed ID: 25250852
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain.
Deer TR; Smith HS; Burton AW; Pope JE; Doleys DM; Levy RM; Staats PS; Wallace MS; Webster LR; Rauck RL; Cousins M;
Pain Physician; 2011; 14(3):E283-312. PubMed ID: 21587338
[TBL] [Abstract][Full Text] [Related]
17. Intractable cancer pain: a new technique for attack in a patient with an implanted intrathecal infusion pump.
Kowal AG; Staats PS
Reg Anesth; 1997; 22(6):584. PubMed ID: 9425980
[No Abstract] [Full Text] [Related]
18. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis.
Kumar K; Hunter G; Demeria DD
J Neurosurg; 2002 Oct; 97(4):803-10. PubMed ID: 12405366
[TBL] [Abstract][Full Text] [Related]
19. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain.
Grider JS; Harned ME; Etscheidt MA
Pain Physician; 2011; 14(4):343-51. PubMed ID: 21785477
[TBL] [Abstract][Full Text] [Related]
20. [Implantable drug pumps for spinal opioid analgesia: technical solutions and problems].
Kehnscherper H; Rudolph S; Freitag B
Anaesthesiol Reanim; 2004; 29(3):74-8. PubMed ID: 15317359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
